Quest Magazine

ALS: Seven Out of 15 Participants in Neuralstem Trial Judged Responders

Maryland-based biotechnology company Neuralstem announced in a March 12, 2014, press release, that a phase 2 trial of its NSI-566 neural stem cells in 15 people with amyotrophic lateral sclerosis (ALS) has shown that the surgical transplantation procedure and the cells

SMA: ISIS-SMNRx To Be Tested in Presymptomatic Infants

Biogen Idec has announced plans to run a phase 2 clinical study of the experimental drug ISIS-SMNRx  in infants with spinal muscular atrophy (SMA)who are less than 6 weeks old and have a genetic diagnosis of the disorder but are not yet showing symptoms. 

MDA Scientific Conference Update: March 14 Morning Sessions

MDA Scientific Conference Update: March 13 Afternoon Sessions

MDA Scientific Conference Update: March 13 Morning Sessions

MDA Underscores Commitment to Frontline Discovery, Breakthroughs at Research Conference

MDA Scientific Conference Update: March 12 Afternoon Sessions

MDA Scientific Conference Update: March 12 A.M. Sessions

MDA 2015 Scientific Conference to Emphasize Urgent Need for Discovery and Treatment

Kroger-Atlanta Division Supports MDA Shamrock Tradition to Help Families Fighting Muscle Disease

Pages